China SXT Pharmaceuticals, Inc. (SXTC) Form 6-K — Oct 21, 2026

China SXT Pharmaceuticals (NASDAQ: SXTC) announced on October 21, 2026 that it terminated the additional purchase right tied to its October 8 registered direct offering. The right had allowed purchasers to buy up to $12 million of additional Class A ordinary shares and/or pre-funded warrants at $1.50 per unit during the 30 days after closing. Under the termination letter agreement, the purchasers no longer have any right, claim, or entitlement to the over-allotment option. All other provisions of the securities purchase agreement remain in full force, and the securities already issued in the offering are unaffected.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.